Anaphylaxis: Trends and Cost Impact in the US
Science & Innovation Webinar
Webinar Recorded on March 3, 2022
Sponsored by Kaléo
Anaphylaxis is a potentially life-threatening allergic reaction characterized by acute onset and rapid progression. The incidence of anaphylaxis has been on the rise, with an increasing number of related emergency department visits and hospitalizations.
This webinar provided a clinical update reviewing trends in epidemiology and the associated cost-burden of anaphylaxis.
Furthermore, the webinar discusses the results of a retrospective claims analysis evaluating healthcare resource utilization and economic impact of patients prescribed AUVI-Q® vs. Other Epinephrine Auto-Injectors.
Please join us for a clinical update of anaphylaxis and a review of the real-world evidence (RWE) study outcomes of AUVI-Q.
Click here to see full AUVI-Q Indication and Important Safety Information at auvi-q.com.
- Vivian P. Hernandez-Trujillo, MD – Board certified Allergist and Pediatrician; Medical Director for Dept of Allergy and Immunology, Nicklaus Children’s Hospital, Miami, Florida
Dr. Hernandez-Trujillo is a paid advisor for kaleo, Inc.
- Eric Burgess, PharmD – Medical Outcomes Liaison, kaleo, Inc.
This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.